US FDA listing of Trajan’s hemaPEN blood microsampling device

US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical (Trajan) has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration (US FDA) as Class I for therapeutic and in vitro diagnostic (IVD) use.

This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

This enables hemaPEN to be used to collect blood microsamples for clinical trials, diagnostics and applications to monitor health.

hemaPEN provides a convenient sampling procedure for collection and storage of four dried blood spot (DBS) samples. Unlike conventional DBS sampling tools, hemaPEN enables collection of an accurate and precise fixed micro-volume and is designed to maintain sample integrity for quantitative analysis. An easy-to-use sophisticated microsampling tool in the hands of non-analysts.

Remote microsampling facilitates more flexible blood sampling compared to traditional phlebotomy (blood draw) for scientific and clinical communities, for rapid R&D and implementation of new healthcare solutions for the public.

Trajan believes in science that benefits people – creating portable and affordable measurement solutions, enabling accurate results to inform preventative healthcare.

Visit www.hemapen.com to purchase or learn more about hemaPEN, and to sign up for updates.

To learn more about Trajan’s microsampling technologies and capabilities visit www.trajanscimed.com/microsampling.




Also in News

Trajan completes ISO 9001 recertification
Trajan completes ISO 9001 recertification

July 14, 2021

Trajan Scientific and Medical has successfully completed a 3-year ISO 9001:2015 recertification at our Ringwood global headquarters this week, cementing the importance that we place over quality management and continuous improvement for ourselves and all stakeholders.

Read More

Global analytical science and device company Trajan Group announces IPO and $50M capital injection to fuel next phase of growth
Global analytical science and device company Trajan Group announces IPO and $50M capital injection to fuel next phase of growth

May 17, 2021

Global analytical science and device company Trajan Group Holdings Limited (Trajan or the Company) has launched a $90 million IPO to support the next phase of accelerated growth.

Read More

Trajan acquires personalised blood testing business to strengthen move into data-based preventative healthcare
Trajan acquires personalised blood testing business to strengthen move into data-based preventative healthcare

April 16, 2021

Trajan Scientific and Medical (Trajan) has completed the acquisition of the MyHealthTest blood testing service for an undisclosed sum. The acquisition further boosts Trajan’s ability to deliver analytical measurement services to society at a time when preventative healthcare strategies are becoming increasingly important.

Read More